Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach

(2022) Yoshiya Tanaka et al.   Nature Reviews Rheumatology

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

(2022) Steven R. Ytterberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study

(2021) Atul Deodhar et al.   ANNALS OF THE RHEUMATIC DISEASES

Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study

(2021) Philip J. Mease et al.   Rheumatology and Therapy

Upadacitinib in Active Ankylosing Spondylitis: 1‐Year Results From the Double‐Blind, Placebo‐Controlled SELECT‐AXIS 1 Study and Open‐Label Extension

(2021) Atul Deodhar et al.   Arthritis & Rheumatology

Axial spondyloarthritis

(2021) Victoria Navarro-Compán et al.   ANNALS OF THE RHEUMATIC DISEASES

A review of JAK–STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition

(2021) Iain B McInnes et al.   RHEUMATOLOGY

Secukinumab improves signs and symptoms of non‐radiographic axial spondyloarthritis: primary results of a randomized controlled phase III study

(2020) Atul Deodhar et al.   Arthritis & Rheumatology

A 52-Week Randomized Placebo-Controlled Trial of Certolizumab Pegol in Non-Radiographic Axial Spondyloarthritis

(2019) Atul Deodhar et al.   Arthritis & Rheumatology

Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts

(2019) Anne Boel et al.   ANNALS OF THE RHEUMATIC DISEASES

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

(2019) Michael M. Ward et al.   Arthritis & Rheumatology

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

(2019) Maxime Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

(2019) Désirée van der Heijde et al.   LANCET

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

(2019) Atul Deodhar et al.   LANCET

Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states

(2018) Pedro M Machado et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study

(2018) Robert Landewé et al.   LANCET

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

(2018) Désirée van der Heijde et al.   LANCET

Axial spondyloarthritis

(2017) Joachim Sieper et al.   LANCET

Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group

(2016) Robert G W Lambert et al.   ANNALS OF THE RHEUMATIC DISEASES

Similarities and differences between nonradiographic and radiographic axial spondyloarthritis

(2014) Denis Poddubnyy et al.   CURRENT OPINION IN RHEUMATOLOGY

Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial

(2012) In-Ho Song et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)

(2012) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores

(2010) P. Machado et al.   ANNALS OF THE RHEUMATIC DISEASES

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection

(2009) M Rudwaleit et al.   ANNALS OF THE RHEUMATIC DISEASES

The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis

(2009) J Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES